New article: Body mass index influence interferon-beta treatment response in multiple sclerosis.
Silje Kvistad and co-authors associated with Kristian Gerhard Jebsen Centre for MS Research and The Norwegian Multiple Sclerosis Competence Centre have recently published an article on obseity and interferon-beta treatment in MS in Journal of Neuroimmunology.
Main content
Obesity is a possible risk factor of multiple sclerosis (MS), but the association between obesity and MS disease activity has not been explored. In a cohort of 86 MS patients, 80% of overweight or obese patients (BMI鈮�25kg/m(2)) had MRI activity compared to 48% of the normal-weight patients (BMI<25kg/m(2)) (p=0.001) during interferon-beta treatment. NEDA-status (no evidence of disease activity) was defined as a composite that consisted of absence of any relapses, sustained disability-progression and MRI-activity. Among normal-weight patients 26% obtained NEDA-status compared to only 13% of patients with BMI >25 (p=0.05). This may indicate that BMI affects interferon-beta treatment response.
听
Referanse:
听